DIA Biosimilars 2013

ViroPharma

ViroPharma expands in PA, creates 151 jobs

Tuesday, September 11, 2012 08:00 AM

ViroPharma, a biopharmaceutical company that focuses on rare diseases, will expand its operations in Exton, Penn., and create 151 new, high-paying jobs.

More... »

Cenduit: Now with Patient Reminders

ViroPharma contracts Recipharm to manufacture Plenadren

Monday, March 19, 2012 09:56 AM

Recipharm, the international contract pharmaceutical development and manufacturing organization, has been contracted by ViroPharma to complete commercial scale-up manufacture of Plenadren (hydrocortisone), used for the treatment of adrenal insufficiency in adults.

More... »

CRF Health – eCOA Forum

ViroPharma initiates phase II study of C1 Esterase Inhibitor

Friday, April 1, 2011 11:13 AM

Pennsylvania-based ViroPharma announced initiation of a phase II clinical study to evaluate the safety and efficacy of C1 Esterase Inhibitor for the treatment of acute antibody-mediated rejection (AMR) in recipients of donor-specific cross-match positive kidney transplants.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs